Biovail Sues Impax Over Wellbutrin XL Patent

Law360, New York (March 9, 2005, 12:00 AM EST) -- A subsidiary of Canadian drug maker Biovail Corp. has filed a lawsuit against Impax Laboratories Inc. over Impax's plans to launch a generic version of Biovail's antidepressant drug Wellbutrin XL.

The lawsuit, filed in the U.S. District Court for the Eastern District of Pennsylvania in Philadelphia, alleges patent infringement related to Impax’s filing for a generic version of the antidepressant with the U.S. Food and Drug Administration.

Impax has submitted its filing under Paragraph IV of the Hatch-Waxman Amendments, stating that it believes its generic versions...
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.